Omega Diagnostics Group (LON:ODX) Stock Rating Reaffirmed by FinnCap

Omega Diagnostics Group (LON:ODX)‘s stock had its “corporate” rating restated by research analysts at FinnCap in a research note issued on Monday, ThisIsMoney.Co.Uk reports.

LON ODX opened at GBX 41.70 ($0.51) on Monday. The company’s 50 day moving average is GBX 56.76 and its 200-day moving average is GBX 27.68. Omega Diagnostics Group has a 12-month low of GBX 6 ($0.07) and a 12-month high of GBX 91.50 ($1.13). The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 18.26. The firm has a market cap of $74.11 million and a P/E ratio of -149.67.

About Omega Diagnostics Group

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases.

Further Reading: LIBOR

Receive News & Ratings for Omega Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.